MEDRAD Builds on Success of P3T Cardiac CT Injectio...(ters is a promising approach. ....),Health

Pulmonary Embolism (PE) is a sudden blood clot or blockage in a lung artery and is a serious condition. At least 100,000 cases of PE occur each year in the United States, according to the National Institutes of Health. PE is the third most common cause of death in hospitalized patients, and if left untreated, kills about 30 percent of patients who have it. Most of those who die do so within the first few hours of the event. CT imaging is often used in the emergency department setting to quickly identify the presence of life-threatening disorders like PE, making efficiency important in quickly and accurately diagnosing the condition. CT has a high specificity and sensitivity in ruling out PE, and researchers in a 2005 meta-analysis (JAMA 2005; 293:2012-17) found that the negative predictive value of a CT angiography of the pulmonary arteries was 99.4%.

MEDRAD, Inc. is a worldwide leading provider of medical devices and services that enable and enhance imaging and therapeutic procedures of the human body. For diagnostic imaging, MEDRAD's product offerings include a comprehensive line of vascular injection systems, magnetic resonance (MR) surface coils and patient care products, and equipment services. The company also offers products used in vascular intervention. MEDRAD's total 2007 revenues were $525 million. In 2003, MEDRAD received the Malcolm Baldrige National Quality Award, the top honor a U.S. company can receive for quality and business excellence. The company's world headquarters is near Pittsburgh, Pennsylvania, in the United States. MEDRAD is an affiliate of Bayer AG. More company information is available at http://www.medrad.com.

The Bayer Group is a global enterprise with core competencies in the fields of healthcare, nutrition and high-tech materials. Bayer HealthCare, a subsidiary of Bayer AG, is one of the w
'/>"/>